Strep A Treatments: Supply Debate
Full Debate: Read Full DebateDepartment: Department for International Trade
Grahame Morris
Main Page: Grahame Morris (Labour - Easington)Department Debates - View all Grahame Morris's debates with the Department for International Trade
Strep A Treatments: Supply
Grahame Morris Excerpts(2 years ago)
Commons ChamberRead Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Urgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Maria Caulfield
I do not want to repeat myself, but we have been clear. We have been working with manufacturers and wholesalers to up production and expedite deliveries to pharmacies, but we recognised fairly early on that that was not going to be enough to meet demand. That is why we already had SSPs in place, so that pharmacists had some flexibility. But we recognised that that was not enough, so on Thursday and Friday we issued five new SSPs so that pharmacists had the flexibility to dispense alternative antibiotics that are as good at dealing with strep A as penicillin V. We will go further. We have more manufacturing plans to increase supply, and we also have alternative provision coming onstream in the next few days, about which I can update the House as well, so we are not just resting on our laurels. We will do whatever it takes to get those antibiotics to those who need them.
Grahame Morris (Easington) (Lab)
The Minister said that there are supply issues but no shortage. I am trying to be helpful here, so may I make a suggestion to improve domestic supply? I recently visited Bristol Laboratories in Peterlee in my constituency—I pay tribute to its management and workforce for their hard work—which has the facilities and the flexible capacity to supply generic medicines to the NHS at relatively short notice. It would seem advantageous to meet Bristol Laboratories and similar manufacturers. UK domestic production capacity for such medications is vital, as was demonstrated during covid. If we do not protect our sovereign manufacturing capability, we risk the UK being at the back of the queue if and when the next global supply shortage or demand surge hits.
Maria Caulfield
If the hon. Gentleman forwards to me the details, I will happily look at that. I would just point out that, as of 12 December, a number of European countries, including Ireland, France, the Netherlands and Sweden have indicated an increase this winter, particularly since September. Antibiotics and amoxicillin are both reported to be in short supply in those countries. This issue is not related solely to the United Kingdom.